Yun-Yao Lu, Yun-Xiao Li, Meng He, Ya-Li Wang, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, Chongqing 400030, China
Co-first authors: Yun-Yao Lu and Yun-Xiao Li.
Co-corresponding authors: Ya-Li Wang and Meng He.
Author contributions: Lu YY designed and performed the research and wrote the manuscript; Wang YL designed the study and supervised the report; Li YX designed the study and participated in the analysis; He M provided clinical advice and supervised the report; All authors were involved in the critical review of the results and have contributed to, read, and approved the final manuscript. Lu YY and Li YX contributed equally to this work and are the first co-authors. Wang YL and He M contributed equally to this study and are co-corresponding authors. There are two reasons for designating Lu YY and Li YX as co-first authors, and Wang YL and He M as co-corresponding authors. First, the research was performed as a collaborative effort, and the designation of co-first authors and co-corresponding authors accurately reflects the distribution of responsibilities and burdens associated with the time and effort required to complete the study and the resultant paper. This also ensures effective communication and management of post-submission matters, ultimately enhancing the paper's quality and reliability. Second, they contributed efforts of equal substance throughout the research process. The choice of these researchers as co-first authors and co-corresponding authors acknowledges and respects this equal contribution, while recognizing the spirit of teamwork and collaboration of this study. In summary, we believe that designating Lu YY and Li YX as co-first authors, and Wang YL and He M as co-corresponding authors is fitting for our manuscript as it accurately reflects our team's collaborative spirit and equal contributions.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the Chongqing University Cancer Hospital (Approval No. CZLS2023170-A).
Informed consent statement: The authors have applied for exemption from obtaining patients’ informed consent.
Conflict-of-interest statement: The authors declare no conflict of interest.
Data sharing statement: The statistical data used in this study can be obtained from the corresponding author upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
https://creativecommons.org/Licenses/by-nc/4.0/ Corresponding author: Ya-Li Wang, MBBS, Technician, Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital, No. 181 Hanyu Road, Shapingba District, Chongqing 400030, China. wangyali19850810@163.com
Received: September 5, 2023
Peer-review started: September 5, 2023
First decision: September 14, 2023
Revised: September 22, 2023
Accepted: November 8, 2023
Article in press: November 8, 2023
Published online: January 27, 2024
Processing time: 141 Days and 22.6 Hours
